Cronos Group Inc. CRON
Cronos is incorporated under the laws of the Province of British Columbia with principal executive offices located at 4491 Concession Rd 12, Stayner, Ontario L0M 1S0. The Company's telephone number is +1-416-504-0004, the website is https://thecronosgroup.com/ and the investor relations section of the website is https://ir.thecronosgroup.com/. All references to Cronos' website are inactive references, are for informational purposes only and are not intended to incorporate any information from or referenced on its website into this Annual Report.
Cronos common shares are currently listed on the Toronto Stock Exchange ("TSX") and on the NASDAQ Global Market ("Nasdaq") under the trading symbol "CRON."
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $146.6M | $117.6M | $87.2M | $86.7M | $64.6M | $46.7M | $23.8M | $12.1M | $3.1M | — |
| Gross profit | $62.8M | $25.2M | $11.9M | $15.4M | -$17.6M | -$25.8M | -$17.6M | $6.2M | $1.6M | — |
| R&D | $4.4M | $4.2M | $5.8M | $13.1M | $21.8M | $20.4M | $12.2M | $1.8M | $0 | — |
| SG&A | $42.0M | $46.5M | $49.5M | $67.7M | $90.9M | $80.6M | $81.5M | $13.3M | $4.9M | — |
| Total operating expenses | $80.2M | $101.7M | $96.7M | $126.9M | $274.4M | $193.6M | $135.7M | $26.7M | $7.7M | — |
| Operating income | -$17.4M | -$76.5M | -$84.8M | -$111.4M | -$292.0M | -$219.4M | -$153.3M | -$20.4M | -$6.1M | — |
| Interest expense | — | — | — | $13.0K | $27.0K | $186.0K | $1.2M | $139.0K | $101.0K | — |
| Pre-tax income | -$17.1M | $36.6M | -$73.7M | -$121.0M | -$128.5M | -$73.3M | $1.17B | -$20.9M | -$2.3M | — |
| Income tax | $14.2M | $3.4M | $3.2M | $34.2M | $431.0K | $1.3M | $0 | $0 | $862.0K | — |
| Net income | -$2.9M | $40.0M | -$73.9M | -$168.7M | -$396.1M | -$73.1M | $1.17B | -$21.6M | -$1.5M | — |
| EPS, basic | -0.02 | 0.11 | -0.19 | -0.45 | -1.07 | -0.21 | 3.76 | -0.12 | -0.01 | — |
| EPS, diluted | -0.02 | 0.11 | -0.19 | -0.45 | -1.07 | -0.21 | 3.33 | -0.12 | -0.01 | — |
| Shares, diluted (wtd. avg.) | $383.5M | $385.6M | $381.0M | $377.0M | $370.4M | $351.6M | $342.8M | $172.3M | $176.8M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $791.8M | $858.8M | $669.3M | $764.6M | $887.0M | $1.08B | $1.20B | $23.9M | $7.3M | $2.6M |
| Short-term investments | $40.0M | $0 | $192.2M | $113.1M | $117.7M | $211.8M | $306.3M | $0 | — | — |
| Receivables | $34.1M | $15.5M | $14.0M | $23.1M | $22.1M | $8.9M | $4.6M | $3.1M | — | — |
| Inventory | $46.8M | $33.1M | $30.5M | $37.6M | $32.8M | $44.0M | $38.0M | $7.4M | — | — |
| Total current assets | $944.1M | $936.1M | $933.3M | $960.2M | $1.08B | $1.37B | $1.57B | $39.9M | — | — |
| Property, plant and equipment | $145.9M | $133.2M | $59.5M | $60.6M | $74.1M | $187.6M | $159.9M | $125.9M | — | — |
| Goodwill | $66.5M | $63.5M | $1.1M | $1.0M | $1.1M | $179.5M | $214.5M | $1.3M | $1.4M | — |
| Other intangibles | $8.9M | $11.3M | $21.1M | $26.7M | $18.1M | $69.7M | $71.2M | $8.2M | — | — |
| Total assets | $1.20B | $1.17B | $1.14B | $1.21B | $1.40B | $1.93B | $2.09B | $183.5M | — | — |
| Accounts payable | $11.6M | $17.0M | $12.1M | $11.2M | $11.1M | $19.3M | $9.2M | $1.2M | — | — |
| Total current liabilities | $48.2M | $49.7M | $41.4M | $68.1M | $54.4M | $206.8M | $332.9M | $33.3M | — | — |
| Total liabilities | $54.2M | $55.3M | $44.1M | $72.0M | $63.5M | $217.5M | $341.4M | $34.9M | — | — |
| Retained earnings | $447.8M | $457.7M | $416.7M | $490.7M | $659.4M | $1.06B | $1.14B | -$27.9M | — | — |
| Total equity | $1.09B | $1.06B | $1.10B | $1.14B | $1.33B | $1.71B | $1.75B | $148.5M | $63.7M | $22.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $25.9M | $18.8M | -$42.8M | -$88.9M | -$153.6M | -$144.9M | -$131.2M | -$7.5M | -$4.3M | — |
| Depreciation and amortisation | $14.2M | $9.3M | $8.1M | $13.1M | $15.4M | $7.0M | $4.3M | $1.9M | $768.0K | — |
| Stock-based compensation | $7.0M | $8.7M | $8.8M | $15.1M | $10.2M | $15.4M | $11.6M | $8.2M | $1.9M | — |
| Capital expenditure | $25.7M | $12.4M | $2.5M | $3.5M | $11.1M | $31.4M | $38.7M | $88.3M | $32.9M | — |
| Investing cash flow | -$76.6M | $175.1M | -$59.5M | -$1.8M | -$28.9M | $20.1M | -$603.3M | -$93.9M | -$29.9M | — |
| Financing cash flow | -$19.9M | -$1.2M | -$1.0M | -$2.9M | -$13.4M | -$3.1M | $1.86B | $122.1M | $39.1M | — |
| Buybacks | $9.7M | $0 | $0 | — | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001656472-26-000021.
Others in SIC 2833
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| DFTX | Definium Therapeutics, Inc. | $5.12B | — | — |
| TRLV | Trulieve Cannabis Corp. | $2.33B | — | -0.4% |
| TLRY | Tilray Brands, Inc. | $612.9M | — | 11.5% |
| CGC | Canopy Growth Corp | $411.5M | — | — |
| USNA | USANA HEALTH SCIENCES INC | $276.4M | 25.8x | 8.3% |
| NAGE | Niagen Bioscience, Inc. | $250.8M | 15.8x | 29.9% |
| FTLF | FITLIFE BRANDS, INC. | $92.2M | 15.6x | 26.4% |
| BTMD | biote Corp. | $44.2M | 2.1x | -2.5% |